Patents by Inventor Wen-Chen YEH

Wen-Chen YEH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liver-specific Wnt signal enhancing molecules and uses thereof
    Patent number: 12240876
    Abstract: The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: March 4, 2025
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Zhengjian Zhang, Randall J. Brezski, Leonard Presta, Thomas Lopez, Hui Chen, Helene Baribault, Wen-Chen Yeh, Shengjiang Tu
  • WNT-SURROGATE AGENTS AND METHODS FOR LACRIMAL GLAND REGENERATION
    Publication number: 20250051459
    Abstract: Methods and compositions for treatment of dry-eye disorders are provided. In particular, the present disclosure provides methods and compositions for modulating WNT (Wingless and lnt-1) signaling in a subject to modulate regeneration of tear-producing acinar cells to treat aqueous-deficient type dry-eye diseases. Further disclosed are WNT signaling modulators used in the methods.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 13, 2025
    Inventors: Yang LI, Huy Tuan NGUYEN, Yorick POST, Wen-Chen YEH
  • MODULATION OF WNT SIGNALLING IN PULMONARY DISORDERS
    Publication number: 20240391991
    Abstract: The present invention provides methods of treating pulmonary disorders with modulators of the Wnt signaling pathway. Also provided are methods of related methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: September 14, 2022
    Publication date: November 28, 2024
    Inventors: Russell FLETCHER, Kuo-Pao LAI, Yang LI, Wen-Chen YEH
  • ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
    Publication number: 20240368287
    Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: May 1, 2024
    Publication date: November 7, 2024
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Chenggang LU, Parthasarathy SAMPATHKUMAR, Claudia Yvonne JANDA
  • TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
    Publication number: 20240279303
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 22, 2024
    Inventors: Zhengjian ZHANG, Jennifer Jean BRADY, Aaron Ken SATO, Wen-Chen YEH, Yang LI, Teppei YAMAGUCHI
  • Anti-frizzled antibodies and methods of use
    Patent number: 12006368
    Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 11, 2024
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Chenggang Lu, Parthasarathy Sampathkumar, Claudia Yvonne Janda
  • MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS
    Publication number: 20240150473
    Abstract: The present disclosure provides engineered WNT agonists and methods of treating gastrointestinal disorders with modulators of the WNT signaling pathway.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 9, 2024
    Inventors: Russell FLETCHER, Sungjin LEE, Yang LI, Chenggang LU, Parthasarathy SAMPATHKUMAR, Geertrui VANHOVE, Wen-Chen YEH, Liqin XIE, Leonard PRESTA
  • ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE
    Publication number: 20240150458
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Application
    Filed: July 11, 2023
    Publication date: May 9, 2024
    Applicant: Surrozen Operating, Inc.
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Parthasarathy SAMPATHKUMAR
  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20240141049
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • Tissue-specific Wnt signal enhancing molecules and uses thereof
    Patent number: 11958891
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 16, 2024
    Assignee: Surrozen Operating, Inc.
    Inventors: Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
  • LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
    Publication number: 20230374090
    Abstract: The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 23, 2023
    Applicant: Surrozen Operating, Inc.
    Inventors: Yang LI, Zhengjian ZHANG, Randall J. BREZSKI, Leonard PRESTA, Thomas LOPEZ, Hui CHEN, Helene BARIBAULT, Wen-Chen YEH, Shengjiang TU
  • WNT surrogate molecules and uses thereof
    Patent number: 11773171
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 3, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
  • WNT RECEPTOR-SPECIFIC COMPOUND AND METHOD RELATING THERETO
    Publication number: 20230295347
    Abstract: The present invention provides compounds which specifically bind to one or more Wnt receptors and methods relating thereto. In some aspects, compositions and methods for treating ocular disorders with modulators of the Wnt signaling pathway are provided. In particular, the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: December 30, 2022
    Publication date: September 21, 2023
    Inventors: Hui CHEN, Sungjin LEE, Yang LI, Wen-Chen YEH
  • Anti-LRP5/6 antibodies and methods of use
    Patent number: 11746150
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 5, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Parthasarathy Sampathkumar
  • MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS
    Publication number: 20220195053
    Abstract: The present invention provides methods of treating gastrointestinal disorders with modulators of the WNT signaling pathway. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 23, 2022
    Applicant: Surrozen Operating Inc.
    Inventors: Yang LI, Chenggang LU, Hélène BARIBAULT, Wen-Chen YEH, Liqin XIE, I-Chieh WANG, Weixu MENG
  • MODULATION OF WNT SIGNALING IN AUDITORY DISORDERS
    Publication number: 20220175884
    Abstract: Methods of treating auditory disorders with modulators of the WNT signaling pathway are disclosed. Also provided are methods of administration and pharmaceutical compositions.
    Type: Application
    Filed: April 1, 2020
    Publication date: June 9, 2022
    Inventors: Sungjin LEE, Yang LI, Wen-Chen YEH
  • MODULATION OF WNT SIGNALLING IN OCULAR DISORDERS
    Publication number: 20220112278
    Abstract: The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: February 11, 2020
    Publication date: April 14, 2022
    Inventors: Yang LI, Shengjiang TU, Sungjin LEE, Wen-Chen YEH
  • TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES
    Publication number: 20210380678
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.
    Type: Application
    Filed: July 9, 2019
    Publication date: December 9, 2021
    Inventors: Zhengjian ZHANG, Yang LI, Wen-Chen YEH, Tom Zhiye YUAN, Helene BARIBAULT, Kuo-Pao LAI
  • Alkyl substituted triazole compounds as agonists of the APJ Receptor
    Patent number: 11191762
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden, Ankit Sharma
  • Heteroaryl-substituted triazoles as APJ receptor agonists
    Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh